(ENSG) The Ensign - Overview
Stock: Skilled Nursing, Senior Living, Rehabilitation
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.17% |
| Yield on Cost 5y | 0.30% |
| Yield CAGR 5y | 4.42% |
| Payout Consistency | 98.6% |
| Payout Ratio | 5.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 31.1% |
| Relative Tail Risk | -8.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.33 |
| Alpha | 24.16 |
| Character TTM | |
|---|---|
| Beta | 0.419 |
| Beta Downside | 0.221 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.49% |
| CAGR/Max DD | 1.29 |
Description: ENSG The Ensign January 07, 2026
The Ensign Group, Inc. (NASDAQ: ENSG) operates a network of skilled-nursing, senior-living, and rehabilitative facilities across 16 U.S. states, delivering both direct patient care (short- and long-term nursing, specialty services such as dialysis and ventilator management) and ancillary services (digital imaging, pharmacy, transportation). Its business is split between the Skilled Services segment, which provides the clinical and residential care, and the Standard Bearer segment, which generates lease income by renting post-acute care properties to other operators.
Key operating metrics show the company’s scale and financial health: as of FY 2023, ENSG reported approximately 6,200 licensed beds with an average occupancy rate of roughly 85%, and total revenue of $1.2 billion, reflecting a 5% year-over-year growth. EBITDA margins have hovered near 12%, while cash flow from operations remains positive, supporting ongoing capital expenditures and debt repayment. Sector-wide, the aging U.S. population and rising demand for post-acute care-driven by higher Medicare Advantage enrollment and tighter hospital discharge policies-are fundamental tailwinds for ENSG’s service lines.
For a deeper dive into ENSG’s valuation metrics, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 328.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.37 > 1.0 |
| NWC/Revenue: 7.90% < 20% (prev 10.42%; Δ -2.52% < -1%) |
| CFO/TA 0.09 > 3% & CFO 481.4m > Net Income 328.2m |
| Net Debt (1.71b) to EBITDA (538.7m): 3.18 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.0m) vs 12m ago 0.88% < -2% |
| Gross Margin: 15.65% > 18% (prev 0.16%; Δ 1550 % > 0.5%) |
| Asset Turnover: 98.00% > 50% (prev 88.76%; Δ 9.25% > 0%) |
| Interest Coverage Ratio: 53.02 > 6 (EBITDA TTM 538.7m / Interest Expense TTM 8.29m) |
Altman Z'' 2.68
| A: 0.07 (Total Current Assets 1.21b - Total Current Liabilities 825.2m) / Total Assets 5.23b |
| B: 0.32 (Retained Earnings 1.66b / Total Assets 5.23b) |
| C: 0.09 (EBIT TTM 439.6m / Avg Total Assets 4.93b) |
| D: 0.54 (Book Value of Equity 1.66b / Total Liabilities 3.10b) |
| Altman-Z'' Score: 2.68 = A |
Beneish M -2.95
| DSRI: 0.94 (Receivables 612.7m/554.1m, Revenue 4.83b/4.11b) |
| GMI: 0.99 (GM 15.65% / 15.51%) |
| AQI: 1.07 (AQ_t 0.07 / AQ_t-1 0.07) |
| SGI: 1.18 (Revenue 4.83b / 4.11b) |
| TATA: -0.03 (NI 328.2m - CFO 481.4m) / TA 5.23b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of ENSG shares?
Over the past week, the price has changed by +14.63%, over one month by +12.25%, over three months by +9.01% and over the past year by +53.31%.
Is ENSG a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ENSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 208.2 | 5.3% |
| Analysts Target Price | 208.2 | 5.3% |
| ValueRay Target Price | 261.5 | 32.2% |
ENSG Fundamental Data Overview February 02, 2026
P/E Forward = 23.2019
P/S = 2.0589
P/B = 4.6477
P/EG = 1.5467
Revenue TTM = 4.83b USD
EBIT TTM = 439.6m USD
EBITDA TTM = 538.7m USD
Long Term Debt = 138.6m USD (from longTermDebt, last quarter)
Short Term Debt = 115.0m USD (from shortTermDebt, last quarter)
Debt = 2.16b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.71b USD (from netDebt column, last quarter)
Enterprise Value = 11.59b USD (9.94b + Debt 2.16b - CCE 506.3m)
Interest Coverage Ratio = 53.02 (Ebit TTM 439.6m / Interest Expense TTM 8.29m)
EV/FCF = 40.04x (Enterprise Value 11.59b / FCF TTM 289.5m)
FCF Yield = 2.50% (FCF TTM 289.5m / Enterprise Value 11.59b)
FCF Margin = 6.00% (FCF TTM 289.5m / Revenue TTM 4.83b)
Net Margin = 6.80% (Net Income TTM 328.2m / Revenue TTM 4.83b)
Gross Margin = 15.65% ((Revenue TTM 4.83b - Cost of Revenue TTM 4.07b) / Revenue TTM)
Gross Margin QoQ = 14.67% (prev 16.19%)
Tobins Q-Ratio = 2.22 (Enterprise Value 11.59b / Total Assets 5.23b)
Interest Expense / Debt = 0.09% (Interest Expense 1.97m / Debt 2.16b)
Taxrate = 21.28% (22.7m / 106.6m)
NOPAT = 346.0m (EBIT 439.6m * (1 - 21.28%))
Current Ratio = 1.46 (Total Current Assets 1.21b / Total Current Liabilities 825.2m)
Debt / Equity = 1.02 (Debt 2.16b / totalStockholderEquity, last quarter 2.12b)
Debt / EBITDA = 3.18 (Net Debt 1.71b / EBITDA 538.7m)
Debt / FCF = 5.92 (Net Debt 1.71b / FCF TTM 289.5m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.66% (Net Income 328.2m / Total Assets 5.23b)
RoE = 16.62% (Net Income TTM 328.2m / Total Stockholder Equity 1.98b)
RoCE = 20.80% (EBIT 439.6m / Capital Employed (Equity 1.98b + L.T.Debt 138.6m))
RoIC = 16.33% (NOPAT 346.0m / Invested Capital 2.12b)
WACC = 6.14% (E(9.94b)/V(12.10b) * Re(7.46%) + D(2.16b)/V(12.10b) * Rd(0.09%) * (1-Tc(0.21)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.21%
[DCF Debug] Terminal Value 84.90% ; FCFF base≈251.0m ; Y1≈241.3m ; Y5≈236.1m
Fair Price DCF = 83.48 (EV 6.55b - Net Debt 1.71b = Equity 4.84b / Shares 57.9m; r=6.14% [WACC]; 5y FCF grow -5.16% → 2.90% )
EPS Correlation: -1.13 | EPS CAGR: -44.31% | SUE: -4.0 | # QB: 0
Revenue Correlation: 99.49 | Revenue CAGR: 18.17% | SUE: 3.37 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.75 | Chg30d=+0.006 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=7.27 | Chg30d=+0.026 | Revisions Net=+1 | Growth EPS=+11.5% | Growth Revenue=+12.6%